CTLA4 and melanoma: Ipilimumab is the first, and only Food and Drug Administration (FDA) approved CTLA-4 inhibitor, which was initially approved in 2011 based on the pivotal Phase 3 MDX010-020 trial that demonstrated an OS advantage in patients with unresectable, previously treated, late-stage melanoma [97].